FIELD: biotechnology.
SUBSTANCE: present group of inventions relates to biotechnology. Disclosed is a humanized anti-CD79b antibody. Also disclosed are a polynucleotide, a vector, a host cell and a method of producing an anti-CD79b antibody; immunoconjugates, compositions, use of the antibody and immunoconjugates for preparing the drug; method of determining presence of CD79b in a sample and a method for producing the immunoconjugate.
EFFECT: present invention can find further application in therapy and diagnostics of diseases associated with CD79b.
57 cl, 20 tbl, 51 dwg, 9 ex
Title | Year | Author | Number |
---|---|---|---|
STABLE COMPOSITIONS OF IMMUNOCONJUGATES CONTAINING ANTIBODIES TO CD79b | 2019 |
|
RU2800803C2 |
ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2008 |
|
RU2511410C2 |
ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2009 |
|
RU2553566C2 |
ANTI-CD79B ANTIBODIES, IMMUNOCONJUGATES AND METHODS FOR THEIR USE | 2019 |
|
RU2791984C2 |
HUMANISED ANTIBODIES AGAINST CD79b AND IMMUNOCONJUGATES AND METHODS OF APPLICATION | 2008 |
|
RU2557319C2 |
ANTIBODIES AND IMMUNOCONJUGATES AND THEIR APPLICATION | 2007 |
|
RU2436796C9 |
TREATMENT OF B-CELLULAR MALIGNANT TUMORS USING ANTI-CD40L ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR BY CHEMOTHERAPY AND RADIOTHERAPY | 2000 |
|
RU2305561C2 |
CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES | 2011 |
|
RU2602878C2 |
COMBINATION THERAPY OF AFUCOSYLATED CD20 ANTIBODY WITH CD79b ANTIBODY-DRUGS CONJUGATE | 2014 |
|
RU2670971C9 |
CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES | 2016 |
|
RU2678818C2 |
Authors
Dates
2019-07-16—Published
2013-12-30—Filed